Help us: Donate
Follow us on:
×

Tag: Kelsey Moody

September 25, 2019
We're continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Dr. Kelsey Moody gave a detailed presentation on macular degeneration, discussing its origins in the lysosomes and how it progresses...
July 08, 2019
There are now only two days to go before the Ending Age-Related Diseases 2019 conference at the Cooper Union in New York City. This is our annual conference that brings together industry leaders from biotech research and business. We have almost sold out of tickets, so if you are thinking about attending, you should act...
June 17, 2019
We are drawing close now to the Ending Age-Related Diseases Conference in New York City, so with less than a month before the big day, today is the ideal time to have a look at what has been happening. Tickets are priced at only $500 and include access to two action-packed days of aging research...
May 28, 2019
A BIOTECH IN A BOX WORKSHOP Alongside our Ending Age-related Diseases 2019 annual conference, we are proud to announce the launch of a special pre-conference biotech workshop led by Dr. Kelsey Moody, CEO of Ichor Therapeutics, a successful and rapidly growing rejuvenation biotechnology company. This joint event between the Life Extension Advocacy Foundation and Ichor...
April 11, 2019
At Undoing Aging 2019, we interviewed some of the best researchers who are involved in discovering therapies for the root causes of aging. Their research aims to ameliorate the damages of aging and may one day lead to a future without the diseases of aging. We were glad to have the opportunity to conduct a...
February 12, 2019
I recently visited the Longevity Leaders Conference in London and had the opportunity to speak with Kelsey Moody, the CEO of Ichor Therapeutics, a company focused on targeting age-related diseases by targeting the aging processes themselves. I previously interviewed him back in 2017, so it was the ideal time to catch up on what had...